New: our quarterly report on the S&P 500, read from 500 companies’ own filings and calls. Read the Q3 2026 report

Scribe Therapeutics Inc.

SCTX

Healthcare Biotechnology

Scribe Therapeutics Inc.’s revenue for fiscal 2025 (year ended December 2025) was $51.2 million.

12.07 1.15 −8.70%

After hours trading: 12.00, down 0.58%, last trade Fri 7:39pm Eastern.

Market cap
$250.4M
P/E
n/m
Fwd P/E FY26e
n/m
Dividend yield
—
F-score
n/a
ROIC
—
Net debt / EBITDA
—
Payout ratio
—
Older periods Dec '25 Mar '26 Jun '26 Sep '26
P/E ratio

+2 more quarters

— 0.00 0.00 0.00
P/S ratio
— 1.84 1.84 10.31
P/FCF ratio
— 0.00 0.00 0.00
P/Operating CF
— (4.75) (4.75) (23.72)
P/B ratio
— 0.00 0.00 2.13
EV/Sales
— 0.36 0.36 3.58
EV/EBITDA
— 0.00 0.00 0.00
EV/FCF
— 0.00 0.00 0.00
Current Ratio
0.97 — 0.57 4.72
Net Debt/EBITDA
— — 4.58 17.26
Debt/Equity
0.00 — 0.00 0.00
Earnings Yield
— (60.70%) (60.70%) (52.93%)
Free Cash Flow Yield
— 0.00% 0.00% 0.00%
Free Cash Flow per Share
— — — (0.78)
Book value per Share
— — (17.97) 8.63
Free Cash Flow
— — — (11.26)
EV/EBIT
— 0.00 0.00 0.00

Show all line items

Columns are period end dates · fundamentals updated Nov 18, 2026